John Imig
Concepts (554)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 68 | 2025 | 560 | 10.150 |
Why?
| | Epoxide Hydrolases | 44 | 2024 | 47 | 9.670 |
Why?
| | Kidney | 64 | 2026 | 716 | 8.450 |
Why?
| | Kidney Diseases | 23 | 2026 | 230 | 7.680 |
Why?
| | Blood Pressure | 56 | 2021 | 525 | 4.350 |
Why?
| | Cytochrome P-450 Enzyme System | 27 | 2020 | 191 | 4.330 |
Why?
| | Ureteral Obstruction | 7 | 2025 | 62 | 3.910 |
Why?
| | 8,11,14-Eicosatrienoic Acid | 18 | 2020 | 18 | 3.790 |
Why?
| | Eicosanoids | 15 | 2022 | 18 | 3.730 |
Why?
| | Vasodilation | 26 | 2020 | 99 | 3.600 |
Why?
| | Animals | 146 | 2026 | 13485 | 3.200 |
Why?
| | Rats | 91 | 2025 | 3228 | 3.060 |
Why?
| | Renal Insufficiency, Chronic | 9 | 2024 | 198 | 3.040 |
Why?
| | Antihypertensive Agents | 21 | 2024 | 129 | 2.930 |
Why?
| | Hydroxyeicosatetraenoic Acids | 15 | 2020 | 19 | 2.490 |
Why?
| | Cardiovascular Diseases | 9 | 2023 | 493 | 2.430 |
Why?
| | Angiotensin II | 32 | 2019 | 156 | 2.410 |
Why?
| | Diabetic Nephropathies | 9 | 2021 | 61 | 2.320 |
Why?
| | Endothelium, Vascular | 13 | 2016 | 263 | 2.320 |
Why?
| | Arachidonic Acids | 9 | 2019 | 22 | 2.060 |
Why?
| | Nephritis | 7 | 2025 | 23 | 2.040 |
Why?
| | Diabetes Mellitus, Experimental | 8 | 2021 | 136 | 2.020 |
Why?
| | Enzyme Inhibitors | 20 | 2021 | 378 | 2.010 |
Why?
| | Sodium Chloride, Dietary | 11 | 2023 | 33 | 1.830 |
Why?
| | Obesity | 13 | 2018 | 1176 | 1.780 |
Why?
| | PPAR gamma | 4 | 2020 | 72 | 1.650 |
Why?
| | Fibrosis | 11 | 2025 | 198 | 1.620 |
Why?
| | Rats, Sprague-Dawley | 47 | 2018 | 1558 | 1.570 |
Why?
| | Acute Kidney Injury | 6 | 2026 | 389 | 1.570 |
Why?
| | Epoxy Compounds | 5 | 2021 | 47 | 1.520 |
Why?
| | Renal Circulation | 14 | 2025 | 56 | 1.520 |
Why?
| | Disease Models, Animal | 25 | 2025 | 1483 | 1.520 |
Why?
| | Male | 99 | 2025 | 26874 | 1.400 |
Why?
| | Protective Agents | 2 | 2026 | 16 | 1.400 |
Why?
| | Diabetes Mellitus, Type 2 | 7 | 2021 | 570 | 1.390 |
Why?
| | Arterioles | 15 | 2025 | 33 | 1.360 |
Why?
| | Lauric Acids | 5 | 2009 | 8 | 1.340 |
Why?
| | Mesenteric Arteries | 9 | 2017 | 39 | 1.310 |
Why?
| | Adamantane | 5 | 2009 | 24 | 1.310 |
Why?
| | Fatty Acids | 3 | 2023 | 152 | 1.300 |
Why?
| | Kidney Glomerulus | 8 | 2018 | 41 | 1.280 |
Why?
| | Vasodilator Agents | 9 | 2018 | 90 | 1.270 |
Why?
| | Benzimidazoles | 6 | 2014 | 50 | 1.260 |
Why?
| | Blood Glucose | 9 | 2021 | 483 | 1.250 |
Why?
| | Oxidative Stress | 15 | 2026 | 805 | 1.230 |
Why?
| | Mice | 35 | 2025 | 5899 | 1.230 |
Why?
| | Sodium Chloride | 6 | 2020 | 55 | 1.170 |
Why?
| | Myocardial Infarction | 5 | 2021 | 449 | 1.120 |
Why?
| | Podocytes | 3 | 2025 | 21 | 1.070 |
Why?
| | Doxorubicin | 2 | 2026 | 246 | 1.040 |
Why?
| | Rats, Inbred SHR | 11 | 2020 | 37 | 1.040 |
Why?
| | Hypertension, Renal | 7 | 2025 | 21 | 1.030 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2026 | 83 | 0.970 |
Why?
| | Mesangial Cells | 1 | 2025 | 8 | 0.950 |
Why?
| | Anthracyclines | 1 | 2026 | 34 | 0.950 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2025 | 29 | 0.930 |
Why?
| | Myocardium | 5 | 2021 | 471 | 0.910 |
Why?
| | Oxadiazoles | 3 | 2014 | 9 | 0.900 |
Why?
| | Mice, Inbred C57BL | 17 | 2025 | 1888 | 0.880 |
Why?
| | Arachidonic Acid | 12 | 2020 | 34 | 0.880 |
Why?
| | Albuminuria | 12 | 2018 | 47 | 0.880 |
Why?
| | Benzoates | 8 | 2014 | 22 | 0.860 |
Why?
| | Inflammation | 13 | 2024 | 649 | 0.850 |
Why?
| | Collagen | 5 | 2024 | 215 | 0.810 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 231 | 0.800 |
Why?
| | Humans | 44 | 2026 | 52441 | 0.780 |
Why?
| | Rats, Transgenic | 16 | 2024 | 21 | 0.760 |
Why?
| | Phosphates | 1 | 2022 | 51 | 0.760 |
Why?
| | Public Health | 1 | 2024 | 224 | 0.740 |
Why?
| | Cyclooxygenase 2 | 5 | 2016 | 47 | 0.740 |
Why?
| | Vasoconstriction | 13 | 2025 | 56 | 0.740 |
Why?
| | Dietary Fats | 4 | 2011 | 134 | 0.720 |
Why?
| | Bradykinin | 3 | 2015 | 18 | 0.720 |
Why?
| | Virus Diseases | 1 | 2022 | 47 | 0.710 |
Why?
| | Hydroxyproline | 2 | 2024 | 19 | 0.710 |
Why?
| | Metabolic Diseases | 1 | 2021 | 48 | 0.680 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2018 | 53 | 0.670 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 5 | 2016 | 25 | 0.660 |
Why?
| | Water-Electrolyte Balance | 1 | 2020 | 29 | 0.650 |
Why?
| | Muscle, Smooth, Vascular | 9 | 2021 | 135 | 0.650 |
Why?
| | Blood Vessels | 1 | 2020 | 73 | 0.650 |
Why?
| | Renin-Angiotensin System | 9 | 2019 | 58 | 0.650 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2018 | 123 | 0.630 |
Why?
| | Rats, Zucker | 8 | 2018 | 73 | 0.610 |
Why?
| | Urea | 7 | 2014 | 80 | 0.610 |
Why?
| | Kidney Transplantation | 1 | 2021 | 199 | 0.600 |
Why?
| | Heart Diseases | 1 | 2021 | 217 | 0.600 |
Why?
| | Liver Cirrhosis | 2 | 2018 | 243 | 0.600 |
Why?
| | Nitric Oxide | 5 | 2016 | 238 | 0.590 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2016 | 28 | 0.590 |
Why?
| | Insulin Resistance | 6 | 2018 | 281 | 0.580 |
Why?
| | Proteinuria | 3 | 2016 | 40 | 0.580 |
Why?
| | Isoenzymes | 5 | 2006 | 171 | 0.570 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 60 | 0.570 |
Why?
| | Ventricular Remodeling | 1 | 2018 | 65 | 0.560 |
Why?
| | Cyclooxygenase 2 Inhibitors | 2 | 2016 | 20 | 0.560 |
Why?
| | Renin | 7 | 2016 | 14 | 0.560 |
Why?
| | Drug Discovery | 1 | 2018 | 94 | 0.540 |
Why?
| | Apoptosis | 9 | 2025 | 1120 | 0.540 |
Why?
| | Membrane Proteins | 3 | 2015 | 344 | 0.530 |
Why?
| | Rats, Inbred WKY | 7 | 2019 | 27 | 0.530 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 4 | 2018 | 44 | 0.530 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 174 | 0.520 |
Why?
| | Kidney Failure, Chronic | 2 | 2009 | 205 | 0.510 |
Why?
| | Neuroprotective Agents | 2 | 2009 | 103 | 0.510 |
Why?
| | Natriuresis | 4 | 2020 | 6 | 0.500 |
Why?
| | Solubility | 5 | 2022 | 81 | 0.500 |
Why?
| | Superoxides | 2 | 2016 | 46 | 0.500 |
Why?
| | Microcirculation | 11 | 2016 | 64 | 0.500 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 39 | 0.490 |
Why?
| | Arachidonate Lipoxygenases | 1 | 2015 | 1 | 0.490 |
Why?
| | Aminopeptidases | 1 | 2015 | 15 | 0.480 |
Why?
| | Brain Ischemia | 2 | 2009 | 168 | 0.480 |
Why?
| | Sodium | 6 | 2023 | 92 | 0.480 |
Why?
| | Cerebral Arteries | 1 | 2015 | 30 | 0.470 |
Why?
| | Rats, Inbred Dahl | 7 | 2025 | 11 | 0.470 |
Why?
| | Metabolome | 1 | 2016 | 100 | 0.470 |
Why?
| | Macrophages | 7 | 2021 | 357 | 0.470 |
Why?
| | Signal Transduction | 11 | 2018 | 1724 | 0.460 |
Why?
| | Angiotensins | 3 | 2010 | 12 | 0.460 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 234 | 0.450 |
Why?
| | Sodium Channel Blockers | 1 | 2014 | 14 | 0.450 |
Why?
| | Tetrazoles | 5 | 2014 | 41 | 0.450 |
Why?
| | Gene Expression | 3 | 2015 | 618 | 0.440 |
Why?
| | Cardiomegaly | 3 | 2021 | 55 | 0.440 |
Why?
| | Lipids | 5 | 2023 | 163 | 0.430 |
Why?
| | Endothelial Cells | 2 | 2013 | 283 | 0.430 |
Why?
| | Homeostasis | 5 | 2016 | 206 | 0.420 |
Why?
| | Hypertension, Renovascular | 4 | 2016 | 12 | 0.420 |
Why?
| | Kidney Tubules, Proximal | 4 | 2013 | 60 | 0.410 |
Why?
| | Captopril | 2 | 2016 | 13 | 0.410 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2010 | 390 | 0.400 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channels | 3 | 2013 | 12 | 0.400 |
Why?
| | Acetylcholine | 5 | 2016 | 56 | 0.400 |
Why?
| | Calcium | 5 | 2021 | 396 | 0.390 |
Why?
| | Cyclooxygenase Inhibitors | 3 | 2016 | 39 | 0.390 |
Why?
| | Cerebrovascular Circulation | 2 | 2011 | 126 | 0.390 |
Why?
| | Enalapril | 3 | 2021 | 12 | 0.390 |
Why?
| | Cyclic N-Oxides | 2 | 2009 | 12 | 0.380 |
Why?
| | Benzenesulfonates | 1 | 2012 | 10 | 0.380 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 5 | 2018 | 73 | 0.380 |
Why?
| | Thiazolidinediones | 1 | 2012 | 81 | 0.380 |
Why?
| | Growth Inhibitors | 1 | 2012 | 26 | 0.370 |
Why?
| | Immunologic Factors | 1 | 2013 | 114 | 0.370 |
Why?
| | Vasoconstrictor Agents | 7 | 2019 | 81 | 0.370 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2012 | 186 | 0.370 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2012 | 12 | 0.370 |
Why?
| | Heart Failure | 3 | 2024 | 527 | 0.370 |
Why?
| | Hypertension, Malignant | 3 | 2018 | 4 | 0.370 |
Why?
| | Dose-Response Relationship, Drug | 10 | 2019 | 1365 | 0.360 |
Why?
| | Sulfones | 3 | 2010 | 24 | 0.360 |
Why?
| | Pyridines | 2 | 2012 | 137 | 0.350 |
Why?
| | Chemokine CCL2 | 7 | 2011 | 65 | 0.350 |
Why?
| | Cisplatin | 1 | 2013 | 282 | 0.350 |
Why?
| | Endoplasmic Reticulum Stress | 4 | 2017 | 51 | 0.350 |
Why?
| | NG-Nitroarginine Methyl Ester | 3 | 2016 | 15 | 0.350 |
Why?
| | Hypoglycemic Agents | 2 | 2012 | 223 | 0.340 |
Why?
| | Potassium Channels | 3 | 2012 | 31 | 0.340 |
Why?
| | Valine | 1 | 2011 | 57 | 0.340 |
Why?
| | Drug Delivery Systems | 2 | 2009 | 148 | 0.340 |
Why?
| | Arrhythmias, Cardiac | 3 | 2021 | 97 | 0.330 |
Why?
| | Actins | 2 | 2024 | 112 | 0.320 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2009 | 5 | 0.320 |
Why?
| | Simvastatin | 1 | 2009 | 27 | 0.310 |
Why?
| | Mice, Knockout | 10 | 2021 | 903 | 0.310 |
Why?
| | Cell Survival | 3 | 2025 | 598 | 0.310 |
Why?
| | Oleic Acids | 1 | 2009 | 8 | 0.310 |
Why?
| | Oxidoreductases | 2 | 2008 | 56 | 0.300 |
Why?
| | Potassium, Dietary | 1 | 2009 | 2 | 0.300 |
Why?
| | Thrombosis | 2 | 2022 | 250 | 0.300 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 217 | 0.300 |
Why?
| | PPAR alpha | 2 | 2006 | 61 | 0.300 |
Why?
| | Gene Deletion | 2 | 2009 | 279 | 0.290 |
Why?
| | Cytochrome P-450 CYP1A1 | 5 | 2018 | 26 | 0.290 |
Why?
| | Hypnotics and Sedatives | 1 | 2009 | 73 | 0.290 |
Why?
| | Receptor, Angiotensin, Type 1 | 4 | 2005 | 56 | 0.290 |
Why?
| | Sulfonamides | 2 | 2022 | 137 | 0.280 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 580 | 0.280 |
Why?
| | Carrier Proteins | 2 | 2013 | 312 | 0.280 |
Why?
| | Potassium Channels, Calcium-Activated | 2 | 2007 | 5 | 0.280 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 1004 | 0.270 |
Why?
| | Receptors, CCR2 | 1 | 2007 | 14 | 0.270 |
Why?
| | Body Weight | 4 | 2014 | 524 | 0.270 |
Why?
| | Hemodynamics | 3 | 2015 | 235 | 0.260 |
Why?
| | Nitric Oxide Synthase | 4 | 2016 | 72 | 0.260 |
Why?
| | Receptors, Prostaglandin E | 2 | 2007 | 2 | 0.260 |
Why?
| | Calcium Channels | 2 | 2005 | 42 | 0.260 |
Why?
| | Drug Evaluation, Preclinical | 4 | 2018 | 141 | 0.260 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2006 | 16 | 0.260 |
Why?
| | Disease Progression | 5 | 2015 | 870 | 0.250 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2019 | 67 | 0.250 |
Why?
| | Glucose Tolerance Test | 2 | 2018 | 61 | 0.250 |
Why?
| | Immunoglobulin G | 2 | 2007 | 193 | 0.250 |
Why?
| | Cholesterol | 3 | 2014 | 159 | 0.240 |
Why?
| | Fenofibrate | 1 | 2006 | 17 | 0.240 |
Why?
| | Heme Oxygenase-1 | 2 | 2019 | 18 | 0.240 |
Why?
| | Hypolipidemic Agents | 1 | 2006 | 30 | 0.240 |
Why?
| | Purinergic P2 Receptor Agonists | 2 | 2005 | 4 | 0.240 |
Why?
| | Cerebral Infarction | 1 | 2005 | 35 | 0.240 |
Why?
| | NF-kappa B | 5 | 2013 | 326 | 0.230 |
Why?
| | Insulin | 5 | 2014 | 485 | 0.230 |
Why?
| | RNA, Messenger | 6 | 2007 | 1134 | 0.230 |
Why?
| | Hyperglycemia | 2 | 2017 | 88 | 0.230 |
Why?
| | Chloride Channels | 2 | 2021 | 26 | 0.230 |
Why?
| | Adenosine Triphosphate | 3 | 2005 | 234 | 0.230 |
Why?
| | Lactones | 1 | 2004 | 25 | 0.220 |
Why?
| | Islets of Langerhans | 2 | 2017 | 28 | 0.220 |
Why?
| | Kidney Cortex | 5 | 2007 | 23 | 0.220 |
Why?
| | Heart | 2 | 2019 | 352 | 0.220 |
Why?
| | Administration, Oral | 5 | 2017 | 455 | 0.210 |
Why?
| | Nephrotic Syndrome | 1 | 2024 | 34 | 0.210 |
Why?
| | Biological Factors | 1 | 2004 | 11 | 0.210 |
Why?
| | Fibroblasts | 3 | 2021 | 357 | 0.210 |
Why?
| | Osteonectin | 3 | 2008 | 10 | 0.210 |
Why?
| | Time Factors | 8 | 2016 | 2987 | 0.210 |
Why?
| | Rats, Inbred Strains | 3 | 2015 | 184 | 0.210 |
Why?
| | Hypertrophy | 1 | 2024 | 53 | 0.210 |
Why?
| | Dinoprostone | 2 | 2007 | 48 | 0.210 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2003 | 2 | 0.210 |
Why?
| | Phenylurea Compounds | 2 | 2014 | 16 | 0.210 |
Why?
| | Receptor, Bradykinin B2 | 1 | 2003 | 7 | 0.210 |
Why?
| | Stroke Volume | 1 | 2024 | 148 | 0.200 |
Why?
| | Thiobarbituric Acid Reactive Substances | 3 | 2013 | 10 | 0.200 |
Why?
| | Osteopontin | 1 | 2022 | 16 | 0.190 |
Why?
| | Minerals | 1 | 2022 | 26 | 0.190 |
Why?
| | Alprostadil | 1 | 2002 | 9 | 0.190 |
Why?
| | Diet, High-Fat | 3 | 2021 | 230 | 0.190 |
Why?
| | Steroid 16-alpha-Hydroxylase | 4 | 2016 | 10 | 0.190 |
Why?
| | Amides | 4 | 2018 | 36 | 0.190 |
Why?
| | Carbazoles | 1 | 2022 | 18 | 0.190 |
Why?
| | Sex Characteristics | 1 | 2024 | 210 | 0.180 |
Why?
| | Substance P | 1 | 2021 | 28 | 0.180 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 4 | 2016 | 75 | 0.180 |
Why?
| | Tachycardia, Ventricular | 1 | 2021 | 45 | 0.180 |
Why?
| | Inflammation Mediators | 3 | 2013 | 113 | 0.180 |
Why?
| | Adaptation, Physiological | 1 | 2002 | 111 | 0.170 |
Why?
| | Desoxycorticosterone | 3 | 2009 | 6 | 0.170 |
Why?
| | Isoprostanes | 1 | 2020 | 2 | 0.170 |
Why?
| | I-kappa B Kinase | 2 | 2011 | 20 | 0.170 |
Why?
| | Paracrine Communication | 1 | 2020 | 13 | 0.170 |
Why?
| | Vascular Stiffness | 1 | 2021 | 24 | 0.170 |
Why?
| | Peptides | 2 | 2015 | 239 | 0.170 |
Why?
| | Down-Regulation | 3 | 2018 | 348 | 0.170 |
Why?
| | Muscle Contraction | 1 | 2021 | 109 | 0.160 |
Why?
| | Metabolic Networks and Pathways | 1 | 2020 | 89 | 0.160 |
Why?
| | Potassium | 1 | 2020 | 54 | 0.160 |
Why?
| | Risk | 1 | 2021 | 315 | 0.160 |
Why?
| | Female | 12 | 2025 | 28277 | 0.160 |
Why?
| | Renal Dialysis | 1 | 2021 | 189 | 0.160 |
Why?
| | Golgi Apparatus | 1 | 2021 | 78 | 0.160 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2020 | 36 | 0.160 |
Why?
| | Receptors, Neurokinin-1 | 1 | 2019 | 10 | 0.160 |
Why?
| | Forecasting | 1 | 2020 | 151 | 0.150 |
Why?
| | Chenodeoxycholic Acid | 1 | 2019 | 7 | 0.150 |
Why?
| | Endothelin-1 | 5 | 2008 | 34 | 0.150 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2012 | 83 | 0.150 |
Why?
| | Mast Cells | 1 | 2019 | 55 | 0.150 |
Why?
| | Cardiotonic Agents | 2 | 2012 | 70 | 0.150 |
Why?
| | KATP Channels | 1 | 2018 | 6 | 0.150 |
Why?
| | 3' Untranslated Regions | 1 | 2018 | 54 | 0.140 |
Why?
| | Drug Therapy, Combination | 4 | 2018 | 404 | 0.140 |
Why?
| | Proteolysis | 1 | 2018 | 100 | 0.140 |
Why?
| | Antioxidants | 3 | 2009 | 255 | 0.140 |
Why?
| | Weight Gain | 3 | 2010 | 235 | 0.140 |
Why?
| | Protein Phosphatase 2 | 2 | 2008 | 4 | 0.140 |
Why?
| | Receptor, Cannabinoid, CB1 | 2 | 2009 | 123 | 0.130 |
Why?
| | Muscle Cells | 2 | 2008 | 20 | 0.130 |
Why?
| | Epithelial Sodium Channels | 2 | 2013 | 8 | 0.130 |
Why?
| | Blood Urea Nitrogen | 2 | 2016 | 40 | 0.130 |
Why?
| | Fatty Liver | 1 | 2018 | 141 | 0.130 |
Why?
| | Carcinoma | 2 | 2008 | 135 | 0.130 |
Why?
| | Vascular Resistance | 2 | 2006 | 47 | 0.130 |
Why?
| | Species Specificity | 2 | 2016 | 194 | 0.130 |
Why?
| | Indomethacin | 1 | 2016 | 36 | 0.120 |
Why?
| | Stereoisomerism | 1 | 2016 | 100 | 0.120 |
Why?
| | Cyclosporine | 1 | 2016 | 65 | 0.120 |
Why?
| | Renal Artery | 1 | 2016 | 32 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 461 | 0.120 |
Why?
| | Receptor, Adenosine A2B | 1 | 2015 | 3 | 0.120 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2016 | 56 | 0.120 |
Why?
| | Whole-Body Irradiation | 1 | 2016 | 128 | 0.120 |
Why?
| | Phosphorylation | 3 | 2013 | 536 | 0.120 |
Why?
| | Ion Channel Gating | 2 | 2006 | 37 | 0.120 |
Why?
| | Radiation-Protective Agents | 1 | 2016 | 69 | 0.120 |
Why?
| | Cytokines | 3 | 2021 | 622 | 0.120 |
Why?
| | Radiation Injuries, Experimental | 1 | 2016 | 80 | 0.120 |
Why?
| | Epigenesis, Genetic | 1 | 2018 | 396 | 0.110 |
Why?
| | Nephrosclerosis | 1 | 2014 | 4 | 0.110 |
Why?
| | Glucose | 2 | 2021 | 356 | 0.110 |
Why?
| | Receptors, Purinergic P2 | 2 | 2005 | 39 | 0.110 |
Why?
| | Calcium Signaling | 2 | 2005 | 57 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2016 | 248 | 0.110 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2014 | 41 | 0.110 |
Why?
| | Glucose Intolerance | 1 | 2014 | 27 | 0.110 |
Why?
| | Ovarian Neoplasms | 2 | 2008 | 455 | 0.110 |
Why?
| | Fructose | 1 | 2013 | 21 | 0.110 |
Why?
| | Coronary Vessels | 2 | 2014 | 169 | 0.110 |
Why?
| | Caspase Inhibitors | 1 | 2013 | 16 | 0.100 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2005 | 180 | 0.100 |
Why?
| | Myocytes, Smooth Muscle | 3 | 2021 | 95 | 0.100 |
Why?
| | Triglycerides | 1 | 2014 | 171 | 0.100 |
Why?
| | Eye Diseases | 1 | 2013 | 33 | 0.100 |
Why?
| | Receptor, Endothelin A | 2 | 2019 | 8 | 0.100 |
Why?
| | Cross-Linking Reagents | 1 | 2013 | 42 | 0.100 |
Why?
| | Retina | 1 | 2013 | 60 | 0.100 |
Why?
| | Rats, Wistar | 2 | 2013 | 223 | 0.100 |
Why?
| | Nephrectomy | 3 | 2019 | 81 | 0.100 |
Why?
| | Inflammasomes | 1 | 2013 | 64 | 0.100 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2013 | 102 | 0.100 |
Why?
| | Cyclic AMP | 2 | 2015 | 90 | 0.100 |
Why?
| | Creatinine | 1 | 2013 | 156 | 0.100 |
Why?
| | Indoles | 4 | 2018 | 283 | 0.100 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 120 | 0.100 |
Why?
| | Interleukin-6 | 3 | 2015 | 271 | 0.100 |
Why?
| | Spin Labels | 2 | 2009 | 6 | 0.100 |
Why?
| | HeLa Cells | 1 | 2013 | 243 | 0.100 |
Why?
| | Angiotensin I | 3 | 2016 | 14 | 0.100 |
Why?
| | Structure-Activity Relationship | 2 | 2017 | 399 | 0.100 |
Why?
| | HEK293 Cells | 1 | 2013 | 236 | 0.100 |
Why?
| | Small Molecule Libraries | 1 | 2013 | 66 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 125 | 0.090 |
Why?
| | Niacinamide | 1 | 2012 | 24 | 0.090 |
Why?
| | Blotting, Western | 4 | 2010 | 587 | 0.090 |
Why?
| | Immunity, Innate | 1 | 2013 | 109 | 0.090 |
Why?
| | Receptors, Angiotensin | 2 | 2002 | 11 | 0.090 |
Why?
| | Syndrome | 1 | 2012 | 247 | 0.090 |
Why?
| | Anti-Inflammatory Agents | 1 | 2013 | 166 | 0.090 |
Why?
| | Platelet Aggregation | 1 | 2012 | 76 | 0.090 |
Why?
| | Transcription Factor RelA | 1 | 2011 | 32 | 0.090 |
Why?
| | Cell Line, Tumor | 2 | 2013 | 1429 | 0.090 |
Why?
| | Catalase | 1 | 2011 | 72 | 0.090 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2011 | 7 | 0.090 |
Why?
| | Neovascularization, Physiologic | 1 | 2012 | 86 | 0.090 |
Why?
| | Cell Adhesion Molecules | 1 | 2011 | 89 | 0.090 |
Why?
| | Models, Biological | 2 | 2021 | 735 | 0.080 |
Why?
| | Pyrrolidines | 3 | 2005 | 65 | 0.080 |
Why?
| | Receptors, Purinergic P2X | 3 | 2005 | 6 | 0.080 |
Why?
| | Cells, Cultured | 3 | 2011 | 1583 | 0.080 |
Why?
| | Hydralazine | 2 | 2014 | 3 | 0.080 |
Why?
| | Reserpine | 2 | 2014 | 13 | 0.080 |
Why?
| | Hydrochlorothiazide | 2 | 2014 | 8 | 0.080 |
Why?
| | Kidney Function Tests | 1 | 2010 | 56 | 0.080 |
Why?
| | Nitrites | 1 | 2010 | 32 | 0.080 |
Why?
| | Biphenyl Compounds | 3 | 2005 | 32 | 0.080 |
Why?
| | Multiple Organ Failure | 1 | 2010 | 48 | 0.080 |
Why?
| | Epithelial Cells | 1 | 2011 | 217 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2013 | 470 | 0.080 |
Why?
| | Receptors, Tumor Necrosis Factor | 2 | 2007 | 36 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2010 | 135 | 0.080 |
Why?
| | TRPV Cation Channels | 1 | 2009 | 11 | 0.080 |
Why?
| | Microvessels | 1 | 2009 | 35 | 0.080 |
Why?
| | Receptors, Cannabinoid | 1 | 2009 | 18 | 0.080 |
Why?
| | Matrix Metalloproteinase 2 | 2 | 2007 | 59 | 0.080 |
Why?
| | Cardiovascular Agents | 1 | 2009 | 65 | 0.080 |
Why?
| | Mice, Obese | 1 | 2009 | 22 | 0.080 |
Why?
| | Endothelins | 2 | 2005 | 17 | 0.080 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 260 | 0.070 |
Why?
| | Aorta | 2 | 2007 | 170 | 0.070 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 148 | 0.070 |
Why?
| | Cattle | 3 | 2014 | 197 | 0.070 |
Why?
| | Receptors, CCR1 | 1 | 2007 | 10 | 0.070 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2008 | 57 | 0.070 |
Why?
| | Ascitic Fluid | 1 | 2007 | 13 | 0.070 |
Why?
| | Capillaries | 2 | 2005 | 53 | 0.070 |
Why?
| | Cell Separation | 2 | 2005 | 78 | 0.070 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2007 | 59 | 0.070 |
Why?
| | Glomerular Filtration Rate | 3 | 2013 | 126 | 0.070 |
Why?
| | Oxygenases | 2 | 2007 | 16 | 0.070 |
Why?
| | Norepinephrine | 2 | 2010 | 106 | 0.070 |
Why?
| | Adult | 1 | 2023 | 14205 | 0.070 |
Why?
| | Charybdotoxin | 1 | 2006 | 1 | 0.060 |
Why?
| | Okadaic Acid | 1 | 2006 | 8 | 0.060 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2006 | 6 | 0.060 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2004 | 22 | 0.060 |
Why?
| | Tetraethylammonium Compounds | 1 | 2006 | 3 | 0.060 |
Why?
| | Leptin | 1 | 2007 | 148 | 0.060 |
Why?
| | Triazoles | 1 | 2007 | 115 | 0.060 |
Why?
| | Arteries | 1 | 2007 | 93 | 0.060 |
Why?
| | Peritoneal Neoplasms | 1 | 2007 | 66 | 0.060 |
Why?
| | NADPH-Ferrihemoprotein Reductase | 1 | 2006 | 14 | 0.060 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2006 | 59 | 0.060 |
Why?
| | Penile Erection | 1 | 2006 | 25 | 0.060 |
Why?
| | Receptor, Endothelin B | 1 | 2005 | 3 | 0.060 |
Why?
| | Immunoblotting | 1 | 2006 | 118 | 0.060 |
Why?
| | Cell Count | 1 | 2005 | 143 | 0.060 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2005 | 88 | 0.060 |
Why?
| | Transcriptional Activation | 1 | 2005 | 127 | 0.060 |
Why?
| | Penis | 1 | 2006 | 85 | 0.060 |
Why?
| | Juxtaglomerular Apparatus | 1 | 2004 | 2 | 0.060 |
Why?
| | Nephrons | 1 | 2004 | 6 | 0.060 |
Why?
| | Molecular Structure | 1 | 2006 | 317 | 0.060 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 2 | 2014 | 16 | 0.060 |
Why?
| | Thromboxane B2 | 1 | 2004 | 4 | 0.060 |
Why?
| | Chemokines | 1 | 2004 | 77 | 0.050 |
Why?
| | Spectrometry, Fluorescence | 1 | 2004 | 46 | 0.050 |
Why?
| | Linoleic Acid | 1 | 2004 | 16 | 0.050 |
Why?
| | Calcium Channels, L-Type | 1 | 2004 | 69 | 0.050 |
Why?
| | Suramin | 1 | 2003 | 13 | 0.050 |
Why?
| | Lipoxygenase | 1 | 2003 | 1 | 0.050 |
Why?
| | Dogs | 1 | 2004 | 183 | 0.050 |
Why?
| | Cell Death | 2 | 2014 | 169 | 0.050 |
Why?
| | Survival Rate | 2 | 2018 | 944 | 0.050 |
Why?
| | Prostaglandins E, Synthetic | 1 | 2002 | 1 | 0.050 |
Why?
| | Receptors, Prostaglandin E, EP2 Subtype | 1 | 2002 | 1 | 0.050 |
Why?
| | Gene Expression Profiling | 1 | 2007 | 1099 | 0.050 |
Why?
| | Heart Rate | 1 | 2004 | 311 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2006 | 318 | 0.050 |
Why?
| | Chemoprevention | 1 | 2022 | 19 | 0.050 |
Why?
| | Endosomes | 1 | 2002 | 34 | 0.050 |
Why?
| | Up-Regulation | 1 | 2003 | 462 | 0.040 |
Why?
| | Biological Transport | 2 | 2013 | 153 | 0.040 |
Why?
| | Promoter Regions, Genetic | 2 | 2016 | 465 | 0.040 |
Why?
| | Peptide Fragments | 2 | 2016 | 214 | 0.040 |
Why?
| | Receptors, Leptin | 1 | 2021 | 52 | 0.040 |
Why?
| | Regional Blood Flow | 2 | 2011 | 109 | 0.040 |
Why?
| | Risk Factors | 1 | 2009 | 3971 | 0.040 |
Why?
| | Sodium, Dietary | 1 | 2021 | 24 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2011 | 5508 | 0.040 |
Why?
| | Rats, Inbred F344 | 2 | 2014 | 194 | 0.040 |
Why?
| | Random Allocation | 2 | 2013 | 286 | 0.040 |
Why?
| | Arterio-Arterial Fistula | 1 | 2019 | 2 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2019 | 57 | 0.040 |
Why?
| | Aging | 1 | 2004 | 722 | 0.040 |
Why?
| | Pinacidil | 1 | 2018 | 1 | 0.040 |
Why?
| | Phenotype | 1 | 2021 | 792 | 0.040 |
Why?
| | Pulmonary Artery | 1 | 2019 | 142 | 0.030 |
Why?
| | Base Sequence | 2 | 2010 | 632 | 0.030 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2017 | 11 | 0.030 |
Why?
| | Mice, Mutant Strains | 2 | 2007 | 72 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2010 | 566 | 0.030 |
Why?
| | Dinoprost | 2 | 2007 | 7 | 0.030 |
Why?
| | Rats, Inbred BN | 1 | 2016 | 13 | 0.030 |
Why?
| | Albumins | 1 | 2016 | 29 | 0.030 |
Why?
| | Hydrogen Peroxide | 2 | 2007 | 122 | 0.030 |
Why?
| | Fas Ligand Protein | 1 | 2016 | 16 | 0.030 |
Why?
| | Cytoprotection | 1 | 2016 | 32 | 0.030 |
Why?
| | Adenosine A2 Receptor Agonists | 1 | 2015 | 5 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2015 | 21 | 0.030 |
Why?
| | Autophagy | 1 | 2017 | 185 | 0.030 |
Why?
| | Aminopyridines | 1 | 2015 | 19 | 0.030 |
Why?
| | Telemetry | 1 | 2015 | 27 | 0.030 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2015 | 34 | 0.030 |
Why?
| | Oxamic Acid | 1 | 2014 | 1 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 168 | 0.030 |
Why?
| | Glomerular Basement Membrane | 1 | 2014 | 9 | 0.030 |
Why?
| | Chemistry Techniques, Synthetic | 1 | 2014 | 21 | 0.030 |
Why?
| | Pressure | 2 | 2006 | 100 | 0.030 |
Why?
| | Orchiectomy | 1 | 2014 | 38 | 0.030 |
Why?
| | Molecular Mimicry | 1 | 2014 | 35 | 0.030 |
Why?
| | Necrosis | 1 | 2014 | 169 | 0.030 |
Why?
| | Cell Proliferation | 2 | 2008 | 1013 | 0.030 |
Why?
| | Sex Factors | 2 | 2008 | 735 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 47 | 0.030 |
Why?
| | Sweetening Agents | 1 | 2013 | 14 | 0.030 |
Why?
| | Epithelial Sodium Channel Blockers | 1 | 2013 | 3 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2013 | 178 | 0.030 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2013 | 27 | 0.030 |
Why?
| | Lipid Peroxidation | 1 | 2013 | 99 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2013 | 165 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 168 | 0.020 |
Why?
| | Muscle Relaxation | 1 | 2012 | 15 | 0.020 |
Why?
| | Isometric Contraction | 1 | 2012 | 20 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2012 | 57 | 0.020 |
Why?
| | Patch-Clamp Techniques | 1 | 2012 | 120 | 0.020 |
Why?
| | Membrane Potentials | 1 | 2012 | 113 | 0.020 |
Why?
| | Amitrole | 1 | 2011 | 1 | 0.020 |
Why?
| | Drug Contamination | 1 | 2011 | 3 | 0.020 |
Why?
| | Losartan | 1 | 2011 | 27 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 641 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2011 | 11 | 0.020 |
Why?
| | Amidines | 1 | 2011 | 8 | 0.020 |
Why?
| | Obesity, Abdominal | 1 | 2011 | 20 | 0.020 |
Why?
| | Renal Plasma Flow | 1 | 2011 | 4 | 0.020 |
Why?
| | Pancreas | 1 | 2011 | 71 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2012 | 294 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2010 | 69 | 0.020 |
Why?
| | DNA Primers | 1 | 2010 | 204 | 0.020 |
Why?
| | Mutation | 1 | 2015 | 1331 | 0.020 |
Why?
| | Androgens | 1 | 2009 | 70 | 0.020 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2008 | 12 | 0.020 |
Why?
| | U937 Cells | 1 | 2008 | 14 | 0.020 |
Why?
| | Luteinizing Hormone | 1 | 2008 | 50 | 0.020 |
Why?
| | Epithelium | 1 | 2008 | 65 | 0.020 |
Why?
| | Follicle Stimulating Hormone | 1 | 2008 | 40 | 0.020 |
Why?
| | HL-60 Cells | 1 | 2008 | 19 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2008 | 142 | 0.020 |
Why?
| | Estrogen Replacement Therapy | 1 | 2008 | 41 | 0.020 |
Why?
| | Cricetulus | 1 | 2008 | 100 | 0.020 |
Why?
| | CHO Cells | 1 | 2008 | 123 | 0.020 |
Why?
| | Organ Specificity | 1 | 2008 | 116 | 0.020 |
Why?
| | Cricetinae | 1 | 2008 | 189 | 0.020 |
Why?
| | Ovary | 1 | 2008 | 101 | 0.020 |
Why?
| | Mineralocorticoids | 1 | 2007 | 2 | 0.020 |
Why?
| | Testosterone | 1 | 2008 | 145 | 0.020 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2007 | 11 | 0.020 |
Why?
| | Receptors, Prostaglandin E, EP1 Subtype | 1 | 2007 | 1 | 0.020 |
Why?
| | Glomerular Mesangium | 1 | 2007 | 7 | 0.020 |
Why?
| | Integrins | 1 | 2007 | 31 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2008 | 278 | 0.020 |
Why?
| | Animals, Genetically Modified | 1 | 2007 | 53 | 0.020 |
Why?
| | Cobalt | 1 | 2007 | 16 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 977 | 0.020 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2007 | 17 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2007 | 72 | 0.020 |
Why?
| | Metalloendopeptidases | 1 | 2007 | 70 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2007 | 162 | 0.020 |
Why?
| | Cyclic GMP | 1 | 2007 | 18 | 0.020 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2007 | 61 | 0.020 |
Why?
| | Heterozygote | 1 | 2007 | 89 | 0.020 |
Why?
| | Estradiol | 1 | 2008 | 226 | 0.020 |
Why?
| | Receptors, Bradykinin | 1 | 2006 | 2 | 0.020 |
Why?
| | Drug Combinations | 1 | 2007 | 136 | 0.020 |
Why?
| | Drug Synergism | 1 | 2006 | 147 | 0.020 |
Why?
| | rho-Associated Kinases | 1 | 2006 | 18 | 0.020 |
Why?
| | Microsomes | 1 | 2006 | 35 | 0.020 |
Why?
| | Viper Venoms | 1 | 2005 | 7 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2006 | 78 | 0.020 |
Why?
| | Electric Stimulation | 1 | 2006 | 115 | 0.020 |
Why?
| | Receptor, Adenosine A1 | 1 | 2005 | 1 | 0.010 |
Why?
| | Uridine Triphosphate | 1 | 2005 | 15 | 0.010 |
Why?
| | Fibronectins | 1 | 2005 | 36 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 2005 | 24 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2006 | 269 | 0.010 |
Why?
| | 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 2005 | 1 | 0.010 |
Why?
| | Gallic Acid | 1 | 2005 | 2 | 0.010 |
Why?
| | Clofibrate | 1 | 2005 | 7 | 0.010 |
Why?
| | Inositol 1,4,5-Trisphosphate | 1 | 2005 | 10 | 0.010 |
Why?
| | Potassium Chloride | 1 | 2005 | 18 | 0.010 |
Why?
| | Diltiazem | 1 | 2005 | 10 | 0.010 |
Why?
| | ortho-Aminobenzoates | 1 | 2005 | 6 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 141 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 2007 | 415 | 0.010 |
Why?
| | Calibration | 1 | 2005 | 56 | 0.010 |
Why?
| | Adenosine | 1 | 2005 | 75 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2005 | 60 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 370 | 0.010 |
Why?
| | Chronic Disease | 1 | 2006 | 579 | 0.010 |
Why?
| | Xanthines | 1 | 2003 | 8 | 0.010 |
Why?
| | Furosemide | 1 | 2003 | 12 | 0.010 |
Why?
| | Diuretics | 1 | 2003 | 25 | 0.010 |
Why?
| | Perfusion | 1 | 2003 | 49 | 0.010 |
Why?
| | Mixed Function Oxygenases | 1 | 2003 | 25 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2005 | 1045 | 0.010 |
Why?
| | Fluoresceins | 1 | 2002 | 9 | 0.010 |
Why?
| | Microvilli | 1 | 2002 | 6 | 0.010 |
Why?
| | Delayed-Action Preparations | 1 | 2002 | 57 | 0.010 |
Why?
| | Dextrans | 1 | 2002 | 16 | 0.010 |
Why?
| | Drug Implants | 1 | 2002 | 35 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2002 | 127 | 0.010 |
Why?
| | Systole | 1 | 2002 | 71 | 0.010 |
Why?
| | Reference Values | 1 | 2002 | 316 | 0.010 |
Why?
| | Antibodies | 1 | 2002 | 144 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2002 | 396 | 0.010 |
Why?
| | Diet | 1 | 2003 | 591 | 0.010 |
Why?
|
|
Imig's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|